Press Releases

Date Title and Summary  
Toggle Summary Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Aug. 22, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of
Toggle Summary Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
MENLO PARK, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
Toggle Summary Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
MENLO PARK, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019 , and recent events. The Company ended the second quarter with $162.3 million in cash and marketable securities.
Toggle Summary Geron to Announce Second Quarter Financial Results on August 1, 2019
MENLO PARK, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on Thursday, August 1, 2019 via press release, which will be available on the Company’s website at
Toggle Summary Geron Enhances Oncology Expertise to Advance Corporate Objectives
MENLO PARK, Calif. , July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments further enhance the Company’s oncology
Toggle Summary Geron Appoints Vice President, Human Resources
MENLO PARK, Calif. , June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations
Toggle Summary Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018 Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased to 29%, from 26% in December 2018 Statistical analyses comparing IMbark clinical trial data to closely matched real-world
Toggle Summary Geron to Webcast KOL Event on June 25, 2019
MENLO PARK, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company will webcast an event on June 25, 2019 , featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the
Toggle Summary Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European
Toggle Summary Geron Provides Imetelstat Program Update
Conference Call Scheduled for 9:00 a.m. ET today MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete,